Related Experiment Video
Updated: May 11, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities)
Insights
Heart failure with preserved ejection fraction (HFpEF) is common in African Americans, more prevalent than reduced ejection fraction (HFrEF) heart failure. HFpEF has a better prognosis than HFrEF but worse than no heart failure.
Area of Science:
- Cardiology
- Public Health
- Epidemiology
Background:
- African Americans exhibit a higher risk of heart failure (HF).
- Limited data exists on the specific characteristics and outcomes of HF with preserved ejection fraction (HFpEF) in this population compared to HF with reduced ejection fraction (HFrEF) and individuals without HF.
Purpose of the Study:
- To compare clinical features, cardiac structure and function, and mortality among African Americans with HFpEF, HFrEF, and no HF.
- To elucidate the unique aspects of HFpEF within an African American cohort.
Main Methods:
- Analysis of the Jackson, Mississippi, ARIC study cohort (n=2,445) including middle-aged African Americans.
- Echocardiography performed between 1993-1995 to assess left ventricular ejection fraction (LVEF).
- Participants categorized into HFpEF (LVEF ≥50%), HFrEF (LVEF <50%), or no HF groups for comparative analysis.
Main Results:
- Heart failure identified in 5.9% of participants; HFpEF constituted 73% of HF cases.
- HFpEF patients were older, more frequently female, and had more comorbidities and concentric hypertrophy than those without HF.
- Compared to HFrEF, HFpEF patients were less likely to have coronary heart disease, diabetes, chronic kidney disease, and eccentric hypertrophy; HFpEF was associated with a 1.51 HR for death vs. no HF, while HFrEF had a 2.50 HR vs. HFpEF.
Conclusions:
- In middle-aged African Americans, HFpEF is the predominant form of heart failure.
- HFpEF carries a significantly better prognosis than HFrEF.
- The prognosis for HFpEF, while better than HFrEF, remains worse than in individuals without heart failure.
Objectives:
In an entirely African-American cohort, we compared clinical characteristics, cardiac structure and function, and all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF) in relation to patients with heart failure with reduced ejection fraction (HFrEF) and those without HF.
Background:
African Americans are at increased risk for HF. Nevertheless, there are limited phenotypic and prognostic data in African Americans with HFpEF compared with those with HFrEF and those without HF.
Methods:
Middle-aged African Americans from the Jackson, Mississippi, cohort of the ARIC (Atherosclerosis Risk In Communities) study (n = 2,445) underwent echocardiography between 1993 and 1995. HF prevalence was available in 1,962 patients for whom left ventricular ejection fraction (LVEF) could be quantified. Participants with HF were categorized as having HFpEF (LVEF ≥50%), HFrEF (LVEF <50%), or no HF, with comparisons made between groups.
Results:
HF was identified in 116 (5.9%) participants (HFpEF n = 85 [73%]; HFrEF n = 31 [27%]). Compared with those without HF, those with HFpEF were older, were more likely to be female, and had more frequent comorbidities and concentric hypertrophy. In relation to HFrEF, those with HFpEF were more likely to be female but less likely to have coronary heart disease, diabetes mellitus, chronic kidney disease, left atrial enlargement, and eccentric hypertrophy. Over a median 13.7 years of follow-up, risk of death differed between groups, with age- and sex-adjusted hazard ratios of 1.51 (95% confidence interval: 1.01 to 2.25) for HFpEF versus those without HF and 2.50 (95% confidence interval: 1.37 to 4.58) for HFrEF versus HFpEF.
Conclusions:
In this cohort of middle-aged African Americans, HFpEF was the most common form of HF and was associated with a substantially better prognosis than HFrEF but worse than those without HF.
Related Concept Videos
Heart Failure II: Pathophysiology
Aortic Regurgitation III: Medical Management
Heart Failure V: Medical Management
Atherosclerosis III: Management
Heart Failure III: Clinical Manifestations
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System